Moore Megan M, Elpern David J, Carter Daniel J
Harvard Medical School, Boston, Massachusetts, USA.
Arch Dermatol. 2004 Feb;140(2):215-7. doi: 10.1001/archderm.140.2.215.
With increasing rates of hepatitis C virus infection and diagnosis, more patients are being treated with interferon alfa-2b plus ribavirin therapy. Cutaneous side effects to combination therapy are common and may limit treatment. There are few previous case reports of generalized eczematous dermatoses occurring after combination therapy for hepatitis C virus, none in a North American patient, and none of this severity or recalcitrance.
A man with chronic hepatitis C virus infection and no history of atopy developed severe, recalcitrant nummular eczema secondary to interferon alfa-2b plus ribavirin combination therapy. The cutaneous side effect was more severe than in previously reported cases and did not remit on discontinuation of therapy.
Greater awareness of the range of dermatologic responses to interferon alfa-2b plus ribavirin therapy may lead to improved surveillance for and treatment of these side effects. Investigating the underlying pathologic mechanisms may ultimately allow for a greater understanding of the immunomodulatory effects of this therapy in the setting of chronic hepatitis C virus infection.
随着丙型肝炎病毒感染率和诊断率的上升,越来越多的患者接受干扰素α-2b联合利巴韦林治疗。联合治疗的皮肤副作用很常见,可能会限制治疗。以前很少有关于丙型肝炎病毒联合治疗后发生泛发性湿疹性皮炎的病例报告,北美患者中没有,也没有这种严重程度或顽固性的病例。
一名患有慢性丙型肝炎病毒感染且无特应性病史的男性,在接受干扰素α-2b联合利巴韦林治疗后出现了严重的、顽固性钱币状湿疹。皮肤副作用比以前报道的病例更严重,并且在停药后并未缓解。
提高对干扰素α-2b联合利巴韦林治疗的皮肤反应范围的认识,可能会改善对这些副作用的监测和治疗。研究潜在的病理机制最终可能有助于更深入地了解这种疗法在慢性丙型肝炎病毒感染情况下的免疫调节作用。